Payment overview · 2025
General Payments
$2,004.11
85 reported records · 12 companies
Healthcare provider profile · identity verified
Jeffrey D Hershkowitz, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · GALESBURG, IL · NPI 1922101104
Verified facts
What the public records show
CMS Open Payments records show Jeffrey D Hershkowitz, D.O. received $2,004.11 in general payments during 2025 across 85 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 385 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 385 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 511 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $414.68 | 20.7% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $294.24 | 14.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $281.57 | 14.1% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $235.76 | 11.8% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $232.46 | 11.6% | 18 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $151.06 | 7.5% | 9 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $121.07 | 6.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $100.44 | 5.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.46 | 3.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.67 | 2.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.93 | 1.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.77 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,996.15 | 84 |
| Education | $7.96 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $276.67 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $271.69 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $254.23 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $232.46 | 18 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $214.88 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $183.01 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $151.06 | 9 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $121.07 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $100.44 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.67 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.67 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.96 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.01 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.82 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.49 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $26.47 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $11.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 239 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 385 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
239 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
385 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
385 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
102 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
119 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
511 | 99 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1255 | 337 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1028 | 230 |
| Gabapentin | Gabapentin | 674 | 151 |
| Lisinopril | Lisinopril | 663 | 158 |
| Furosemide | Furosemide | 638 | 132 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 570 | 113 |
| Omeprazole | Omeprazole | 560 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 551 | 155 |
| Losartan Potassium | Losartan Potassium | 529 | 143 |
| Eliquis | Apixaban | 511 | 99 |
| Potassium Chloride | Potassium Chloride | 480 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 453 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 403 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 398 | 90 |
| Jardiance | Empagliflozin | 385 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 377 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 371 | 99 |
| Sertraline Hcl | Sertraline Hcl | 326 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 292 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 280 | 76 |
| Finasteride | Finasteride | 265 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 79 |
| Alendronate Sodium | Alendronate Sodium | 254 | 70 |
| Allopurinol | Allopurinol | 254 | 65 |
| Tramadol Hcl | Tramadol Hcl | 254 | 61 |
| Spironolactone | Spironolactone | 244 | 53 |
| Carvedilol | Carvedilol | 242 | 45 |
| Lorazepam | Lorazepam | 241 | 50 |
| Farxiga | Dapagliflozin Propanediol | 239 | 43 |
| Metformin Hcl Er | Metformin Hcl | 238 | 63 |
| Warfarin Sodium | Warfarin Sodium | 232 | 42 |
| Memantine Hcl | Memantine Hcl | 205 | 31 |
| Ezetimibe | Ezetimibe | 201 | 50 |
| Trazodone Hcl | Trazodone Hcl | 201 | 44 |
| Alprazolam | Alprazolam | 200 | 42 |
| Irbesartan | Irbesartan | 184 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 184 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 80 |
| Donepezil Hcl | Donepezil Hcl | 183 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 42 |
| Metformin Hcl | Metformin Hcl | 172 | 42 |
| Prednisone | Prednisone | 171 | 65 |
| Atenolol | Atenolol | 165 | 39 |
| Ozempic | Semaglutide | 163 | 39 |
| Simvastatin | Simvastatin | 161 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 156 | 35 |
| Divalproex Sodium | Divalproex Sodium | 149 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 45 |
| Ondansetron Odt | Ondansetron | 136 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 131 | 26 |
| Meloxicam | Meloxicam | 130 | 49 |
| Montelukast Sodium | Montelukast Sodium | 129 | 29 |
| Tradjenta | Linagliptin | 126 | 22 |
| Baclofen | Baclofen | 123 | 24 |
| Clonazepam | Clonazepam | 123 | 23 |
| Xarelto | Rivaroxaban | 121 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 120 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 120 | 33 |
| Entresto | Sacubitril/Valsartan | 119 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 27 |
| Lovastatin | Lovastatin | 113 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 108 | 22 |
| Famotidine | Famotidine | 107 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 106 | 22 |
| Mirtazapine | Mirtazapine | 106 | 30 |
| Pregabalin | Pregabalin | 103 | 29 |
| Trulicity | Dulaglutide | 102 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 26 |
| Levetiracetam | Levetiracetam | 94 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 19 |
| Cephalexin | Cephalexin | 92 | 63 |
| Clonidine Hcl | Clonidine Hcl | 90 | 20 |
| Celecoxib | Celecoxib | 88 | 22 |
| Glimepiride | Glimepiride | 86 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 37 |
| Buspirone Hcl | Buspirone Hcl | 83 | 17 |
| Azithromycin | Azithromycin | 78 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 18 |
| Diazepam | Diazepam | 76 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 17 |
| Olanzapine | Olanzapine | 74 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 49 |
| Glipizide | Glipizide | 71 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 70 | 16 |
| Linzess | Linaclotide | 70 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 40 |
| Bupropion Xl | Bupropion Hcl | 57 | 16 |
| Latanoprost | Latanoprost | 57 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | 11 |
| Nifedipine Er | Nifedipine | 54 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 19 |
| Meclizine Hcl | Meclizine Hcl | 53 | 19 |
| Nystatin | Nystatin | 52 | 27 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 51 | 12 |
| Kerendia | Finerenone | 50 | 13 |
| Midodrine Hcl | Midodrine Hcl | 50 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 49 | suppressed |
| Sucralfate | Sucralfate | 48 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 48 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 11 |
| Primidone | Primidone | 47 | suppressed |
| Mounjaro | Tirzepatide | 46 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Methylprednisolone | Methylprednisolone | 44 | 39 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 11 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 41 | 11 |
| Fentanyl | Fentanyl | 41 | 15 |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | 12 |
| Novolog Flexpen | Insulin Aspart | 40 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 13 |
| Amoxicillin | Amoxicillin | 38 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Ramipril | Ramipril | 38 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 38 | 11 |
| Acetic Acid | Acetic Acid | 36 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 32 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Haloperidol | Haloperidol | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 22 |
| Fenofibrate | Fenofibrate,micronized | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 30 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 13 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Nabumetone | Nabumetone | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 15 |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Tresiba | Insulin Degludec | 20 | suppressed |
| Verapamil Sr | Verapamil Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Methadone Hcl | Methadone Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Azathioprine | Azathioprine | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 14 |
| Nystop | Nystatin | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,004.11 · 85 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, DUPIXENT, EVENITY, FARXIGA, FREESTYLE LIBRE 2, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error